Evolving Management Options for Alopecia Areata: Clinical Burden, Cost-Effective Care, and Emerging Treatments

his CE activity is jointly provided by Global Education Group and Integrity Continuing Education, Inc.
Global Education Group Integrity Continuing Education

This activity is supported by educational grants from Pfizer, Inc.

RELEASE DATE:

January 18, 2023

EXPIRATION DATE:

January 18, 2024

Activity Description

The hair loss that occurs in patients with alopecia areata (AA) imposes a significant psychological burden on the over 300,000 US individuals affected by the disease each year. Traditionally, AA management has been limited to the off-label use of various treatments, many of which can be associated with significant side effects and often provide only limited relief. As understanding of AA pathophysiology has evolved, we have witnessed the development of a number of novel targeted therapies. Foremost among these are multiple JAK inhibitors, one of which has just been approved by the FDA.

Join our esteemed faculty for a review of the recently approved and emerging JAK inhibitor therapies for AA. Complemented with case-based learning and faculty roundtable discussions, designed to help providers achieve better outcomes for their patients with AA.

Target Audience

This educational activity has been designed for community pharmacists, specialty pharmacists, and healthcare professionals in allergy, immunology, dermatology, and managed care who manage patients with AA.

Learning ObjectiveS

Upon successful completion of this educational activity, participants should be better able to:

  • Outline the pathophysiology and clinical burden of AA
  • Review clinical data on emerging agents for AA to determine their potential placement in the treatment landscape
  • Identify the pharmacoeconomic factors associated with emerging AA therapies

Faculty

Brett KingBrett King, MD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, Connecticut
Eric CannonEric Cannon, PharmD, FAMCP
Chief Pharmacy Officer
SelectHealth
Murray, Utah
Dana McCormickDana McCormick, RPh, FAMCP
Director of Pharmacy
Blue Cross Blue Shield
Grapevine, Texas

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CE credit for this activity. During the period of January 18, 2023, through January 18, 2024, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity. Credit cannot be issued after 60 days.

ACCREDITATION STATEMENTS

PHARMACIST CONTINUING EDUCATION
acpeGlobal Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

UAN: 0530-9999-22-111-H01-P
Credits: 1.0 hours (0.10 ceu)

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 60 Minutes

Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-111-H01-P)

This is a knowledge-based activity.

Published

January 18, 2023

Expires

January 18, 2024


CONTACT INFORMATION

For information about ACPE accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Brett King, MD
Advisory Boards, Consultant: AbbVie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals Inc, Eli Lilly and Company, Equillium, Horizon Therapeutics, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer, Inc., Regeneron Pharmaceuticals, Sanofi Genzyme, TWi Biotechnology Inc, Viela Bio
Speaker: AbbVie, Eli Lilly and Company, Incyte, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
Investigator: AnaptysBio, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Eli Lilly and Company, Pfizer, Inc.

Dana McCormick, RPh, FAMCP
No relevant financial relationships to disclose.

Eric Cannon, PharmD, FAMCP
No relevant financial relationships to disclose.

The planners and managers have the following relevant financial relationships with ineligible companies:

Olivia Benevento
No relevant financial relationships to disclose.

Lindsay Borvansky
No relevant financial relationships to disclose.

NyQwayah Brown
No relevant financial relationships to disclose.

Ashley Cann
No relevant financial relationships to disclose.

Stefani Chiarolanza
No relevant financial relationships to disclose.

Andrea Funk
No relevant financial relationships to disclose.

Liddy Knight
No relevant financial relationships to disclose.

Brittany Puster
No relevant financial relationships to disclose.

Lauren Sinclair
No relevant financial relationships to disclose.

Patima Tanapat, PhD
No relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and...
(continued)

MINIMUM SYSTEM REQUIREMENTS

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.